ArticleClinical and experimental hepatology2026
Estrogen receptor β activation attenuates portal hypertension and restores mesenteric vascular reactivity in cirrhotic rats
Article in Clinical and experimental hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: This study investigated estrogen receptor (ER) subtype-specific effects on vascular hyporeactivity in cirrhotic portal hypertension (PHT), focusing on RhoA/ROCK signaling and β-arrestin-2. Material and methods: Cirrhosis and PHT were established by subcutaneous injection of CCl Results: In cirrhotic rats, portal pressure was significantly elevated, and the dose-response curve of mesenteric arterioles to norepinephrine (NE) exhibited a rightward shift with reduced amplitude. Compared to cirrhotic rats, the CCl Conclusions: ERβ activation improves vascular hyporesponsiveness in cirrhosis by modulating β-arrestin-2, suggesting that ERβ may represent a novel therapeutic target for cirrhosis and PHT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.